Model inputs for cost effectiveness analysis cervical colorectal cancer control in WHO sub-Saharan African sub-region AfrE and South East Asian sub-region SearD
| Variable | Assumption | Data source |
|---|---|---|
| Efficacy of HPV vaccination against HPV genotypes 16 and 18 | 100% | Kim et al17 |
| Cervical smear test: | Goldie et al21 | |
| Sensitivity of detecting low grade lesions | 0.60 | |
| Specificity of detecting low grade lesions | 0.95 | |
| HPV DNA testing: | Goldie et al21 | |
| Sensitivity of detecting low grade lesions | 0.84 | |
| Specificity of detecting low grade lesions | 0.88 | |
| Visual inspection with acid (VIA): | Goldie et al21 | |
| Sensitivity of detecting low grade lesions | 0.68 | |
| Specificity of detecting low grade lesions | 0.85 | |
| Cervical smear + HPV DNA tests combined: | Kim et al22 | |
| Sensitivity of detecting low grade lesions | 0.94 | |
| Specificity of detecting low grade lesions | 0.93 | |
| Disability weight for cervical cancer | 0.075 | Murray and Lopez12 |
HPV= human papillomavirus
Estimates of incidence and case fatality reductions derived from modelling the above data are listed in table A3.1 in appendix 3 on bmj.com.